Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)

Lilly

Status and phase: Completed; Phase 3; Phase 2

Conditions: Attention Deficit Hyperactivity Disorder

Treatments: Drug: Placebo; Drug: Atomoxetine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00191295

5285

B4Z-JE-LYBC

Details and patient eligibility

About

Atomoxetine versus placebo in Children with Attention-Deficit/Hyperactivity Disorder (ADHD)

Sex: All

Ages: 6 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients are diagnosed with ADHD
• Patients must be able to swallow capsules
• Patients must be of normal intelligence

Exclusion criteria

• Patients who weigh less than 15 kg or more than 75 kg
• Patients with organic brain disease (for example, dementia or traumatic brain injury residual)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind